ES2147162A1 - "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". - Google Patents

"s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".

Info

Publication number
ES2147162A1
ES2147162A1 ES009900159A ES9900159A ES2147162A1 ES 2147162 A1 ES2147162 A1 ES 2147162A1 ES 009900159 A ES009900159 A ES 009900159A ES 9900159 A ES9900159 A ES 9900159A ES 2147162 A1 ES2147162 A1 ES 2147162A1
Authority
ES
Spain
Prior art keywords
rest
group
treatment
nitrosothiols
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009900159A
Other languages
English (en)
Other versions
ES2147162B1 (es
Inventor
Moliner Jose Repolles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Riudavets Juan Antonio Cerda
Rofes Cristina Negrie
Llorente Lydia Cabeza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacer SA
Original Assignee
Lacer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009900159A priority Critical patent/ES2147162B1/es
Application filed by Lacer SA filed Critical Lacer SA
Priority to OA1200100195A priority patent/OA11823A/en
Priority to SI200030236T priority patent/SI1157987T1/xx
Priority to APAP/P/2001/002247A priority patent/AP1439A/en
Priority to EA200100823A priority patent/EA003577B1/ru
Priority to PT00900518T priority patent/PT1157987E/pt
Priority to PL349006A priority patent/PL202372B1/pl
Priority to HR20010562A priority patent/HRP20010562B1/xx
Priority to IDW00200101662A priority patent/ID29777A/id
Priority to AT00900518T priority patent/ATE249428T1/de
Priority to JP2000595971A priority patent/JP3795330B2/ja
Priority to CNB008030847A priority patent/CN1166631C/zh
Priority to EP00900518A priority patent/EP1157987B1/en
Priority to NZ513162A priority patent/NZ513162A/xx
Priority to MXPA01007570A priority patent/MXPA01007570A/es
Priority to CZ20012678A priority patent/CZ298871B6/cs
Priority to AU30460/00A priority patent/AU764725B2/en
Priority to YUP-536/01A priority patent/RS50072B/sr
Priority to BRPI0007395-4A priority patent/BR0007395B1/pt
Priority to PCT/ES2000/000019 priority patent/WO2000044714A1/es
Priority to EEP200100389A priority patent/EE04524B1/xx
Priority to TR2001/02003T priority patent/TR200102003T2/xx
Priority to IL14438100A priority patent/IL144381A/xx
Priority to DE10083902T priority patent/DE10083902T1/de
Priority to HK02103982.2A priority patent/HK1043586A1/en
Priority to GEAP20006075A priority patent/GEP20043220B/en
Priority to CA002359027A priority patent/CA2359027C/en
Priority to ES00900518T priority patent/ES2206178T3/es
Priority to DE60005154T priority patent/DE60005154T2/de
Priority to GB0120581A priority patent/GB2363604B/en
Priority to HU0105203A priority patent/HUP0105203A3/hu
Priority to DK00900518T priority patent/DK1157987T3/da
Priority to KR1020017009522A priority patent/KR100671878B1/ko
Publication of ES2147162A1 publication Critical patent/ES2147162A1/es
Application granted granted Critical
Publication of ES2147162B1 publication Critical patent/ES2147162B1/es
Priority to NO20013385A priority patent/NO326806B1/no
Priority to IS6020A priority patent/IS2153B/is
Priority to US09/912,164 priority patent/US6800612B2/en
Priority to ZA200106182A priority patent/ZA200106182B/en
Priority to CU20010181A priority patent/CU23098A3/es
Priority to BG105824A priority patent/BG64983B1/bg
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

S-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias. Se describen nuevos S-nitrosotioles derivados de la penicilamina o el glutatión que responden a la fórmula general (I) en la que: A y B son grupos fenilo o bien, conjuntamente, conforman el resto -CH{sub,2 -Q-CH{sub,2 - constituyendo un anillo de seis unidades en el que Q representa un átomo de oxígeno o de azufre o un resto N-R{sup,3 , en el que R{sup,3 es hidrógeno o un grupo alquilo C{sub,1 -C{sub,4 ; R{sup,1 es un resto acilo, que puede ser un acilo alifático C{sub,1 -C{sub,5 o un resto de ácido glutámico unido por medio de su carboxilo no aminoacídico; R{sup,2 es un grupo hidroxilo o un resto de glicina unido mediante un enlace peptídico; de manera que cuando R{sup,1 es un resto acilo alifático R{sup,2 es un grupo hidroxilo, y cuando R{sup,1 es un resto de ácido glutámico R{sup,2 es un resto de glicina. Los nuevos compuestos presentan actividad vasodilatadora e inhibidora de la agregación de las plaquetas,lo que los hace útiles para el tratamiento de disfunciones del sistema circulatorio, especialmente a nivel cardiovascular.
ES009900159A 1999-01-27 1999-01-27 "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". Expired - Fee Related ES2147162B1 (es)

Priority Applications (39)

Application Number Priority Date Filing Date Title
ES009900159A ES2147162B1 (es) 1999-01-27 1999-01-27 "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
TR2001/02003T TR200102003T2 (tr) 1999-01-27 2000-01-19 Dolaşım bozukluklarının tedavisi için etkin madde olarak S-nitrozo tiyoller
APAP/P/2001/002247A AP1439A (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions.
EA200100823A EA003577B1 (ru) 1999-01-27 2000-01-19 S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения
PT00900518T PT1157987E (pt) 1999-01-27 2000-01-19 S-nitrosotiois como agentes para o tratamento de disfuncoes circulatorias
PL349006A PL202372B1 (pl) 1999-01-27 2000-01-19 Pochodne S-nitrozotiolowe penicyloaminy lub glutationu oraz kompozycja farmaceutyczna je zawierająca do leczenia zaburzenia czynności krążenia
HR20010562A HRP20010562B1 (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
IDW00200101662A ID29777A (id) 1999-01-27 2000-01-19 S-nitrosotiol sebagai zat-zat untuk pengobatan gangguan fungsi peredaran darah
AT00900518T ATE249428T1 (de) 1999-01-27 2000-01-19 S-nitrosothiole als agentien zur behandlung von fehlfunktionen des kreislaufs
JP2000595971A JP3795330B2 (ja) 1999-01-27 2000-01-19 循環器障害の治療薬としてのｓ−ニトロソチオール
CNB008030847A CN1166631C (zh) 1999-01-27 2000-01-19 S-亚硝基硫醇作为治疗循环机能障碍的药剂
EP00900518A EP1157987B1 (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
NZ513162A NZ513162A (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
MXPA01007570A MXPA01007570A (es) 1999-01-27 2000-01-19 S-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias.
CZ20012678A CZ298871B6 (cs) 1999-01-27 2000-01-19 S-Nitrosothioly jako prostredky pro lécení obehových dysfunkcí
AU30460/00A AU764725B2 (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
YUP-536/01A RS50072B (sr) 1999-01-27 2000-01-19 S-nitrozotioli kao agensi za tretman cirkulatornih poremećaja
DE10083902T DE10083902T1 (de) 1999-01-27 2000-01-19 S-Nitrosothiole als Mittel zur Behandlung von Kreislauf-Fehlfunktionen
PCT/ES2000/000019 WO2000044714A1 (es) 1999-01-27 2000-01-19 S-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias
EEP200100389A EE04524B1 (et) 1999-01-27 2000-01-19 S-nitrosotioolid kui ained vereringeh„irete raviks
OA1200100195A OA11823A (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions.
BRPI0007395-4A BR0007395B1 (pt) 1999-01-27 2000-01-19 compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias.
SI200030236T SI1157987T1 (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
HK02103982.2A HK1043586A1 (en) 1999-01-27 2000-01-19 S-nitrosothiol as a medicine to treat circulatory dysfunction
GEAP20006075A GEP20043220B (en) 1999-01-27 2000-01-19 S-Nitrosothiols as Agents for The Treatment of Circulatory Dysfunctions
CA002359027A CA2359027C (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
ES00900518T ES2206178T3 (es) 1999-01-27 2000-01-19 S-nitrosotrioles como agentes para el tratamiento de trastornos circulatorios.
DE60005154T DE60005154T2 (de) 1999-01-27 2000-01-19 S-nitrosothiole als agentien zur behandlung von fehlfunktionen des kreislaufs
GB0120581A GB2363604B (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dsyfunctions
HU0105203A HUP0105203A3 (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions and their use
DK00900518T DK1157987T3 (da) 1999-01-27 2000-01-19 S-nitrosothioler som midler til behandling af kredsløbsforstyrrelser
KR1020017009522A KR100671878B1 (ko) 1999-01-27 2000-01-19 순환기 장애 치료제로서의 ｓ-니트로소티올
IL14438100A IL144381A (en) 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
NO20013385A NO326806B1 (no) 1999-01-27 2001-07-06 S-nitrosotioler som midler for behandling av sirkulatoriske dysfunksjoner
IS6020A IS2153B (is) 1999-01-27 2001-07-23 S-nítrósóþíól til meðferðar við blóðrásartruflunum
US09/912,164 US6800612B2 (en) 1999-01-27 2001-07-24 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
ZA200106182A ZA200106182B (en) 1999-01-27 2001-07-26 S-nitrosothiols as agents for the treatment of circulatory dysfunctions.
CU20010181A CU23098A3 (es) 1999-01-27 2001-07-30 S-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias
BG105824A BG64983B1 (bg) 1999-01-27 2001-08-16 S-нитрозотиоли като средства за лечение на нарушени функции на кръвообращението

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009900159A ES2147162B1 (es) 1999-01-27 1999-01-27 "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".

Publications (2)

Publication Number Publication Date
ES2147162A1 true ES2147162A1 (es) 2000-08-16
ES2147162B1 ES2147162B1 (es) 2001-03-16

Family

ID=8307080

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009900159A Expired - Fee Related ES2147162B1 (es) 1999-01-27 1999-01-27 "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
ES00900518T Expired - Lifetime ES2206178T3 (es) 1999-01-27 2000-01-19 S-nitrosotrioles como agentes para el tratamiento de trastornos circulatorios.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00900518T Expired - Lifetime ES2206178T3 (es) 1999-01-27 2000-01-19 S-nitrosotrioles como agentes para el tratamiento de trastornos circulatorios.

Country Status (37)

Country Link
US (1) US6800612B2 (es)
EP (1) EP1157987B1 (es)
JP (1) JP3795330B2 (es)
KR (1) KR100671878B1 (es)
CN (1) CN1166631C (es)
AP (1) AP1439A (es)
AT (1) ATE249428T1 (es)
AU (1) AU764725B2 (es)
BG (1) BG64983B1 (es)
BR (1) BR0007395B1 (es)
CA (1) CA2359027C (es)
CU (1) CU23098A3 (es)
CZ (1) CZ298871B6 (es)
DE (2) DE10083902T1 (es)
DK (1) DK1157987T3 (es)
EA (1) EA003577B1 (es)
EE (1) EE04524B1 (es)
ES (2) ES2147162B1 (es)
GB (1) GB2363604B (es)
GE (1) GEP20043220B (es)
HK (1) HK1043586A1 (es)
HR (1) HRP20010562B1 (es)
HU (1) HUP0105203A3 (es)
ID (1) ID29777A (es)
IL (1) IL144381A (es)
IS (1) IS2153B (es)
MX (1) MXPA01007570A (es)
NO (1) NO326806B1 (es)
NZ (1) NZ513162A (es)
OA (1) OA11823A (es)
PL (1) PL202372B1 (es)
PT (1) PT1157987E (es)
RS (1) RS50072B (es)
SI (1) SI1157987T1 (es)
TR (1) TR200102003T2 (es)
WO (1) WO2000044714A1 (es)
ZA (1) ZA200106182B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2173044B1 (es) * 2001-03-13 2004-01-16 Lacer Sa Derivados de glicina, n-(n-l-gamma-glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.
AU2004275809A1 (en) * 2003-09-26 2005-04-07 Nitromed, Inc. Nitrosated glutamic acid compounds, compositions and methods of use
EP1939179A1 (en) * 2006-12-28 2008-07-02 Lacer, S.A. Stable S-nitrosothiols, method of synthesis and use
PL2197417T3 (pl) 2007-10-17 2012-08-31 Pharmagenix Ag Kompozycja farmaceutyczna zawierająca S-nitrozoglutation i polisacharyd

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (en) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Nitrosothiol derivatives, their production and use
US5187305A (en) * 1990-11-26 1993-02-16 Glaxo Inc. S-nitroso-N-alkonoylpenicillamines
WO1995007691A1 (en) * 1993-09-17 1995-03-23 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37839A (en) * 1863-03-03 Improved spoke-machine
GB1567561A (en) 1977-01-18 1980-05-14 Ucb Sa Amino-spiro(oxa-(orthia)cycloalkane-penam) - carboxylic acids
GB2052497B (en) 1979-06-25 1983-06-29 Ucb Sa 6 - amino - spiro - (penam - 2,4' - piperidine) - 3 - carboxylic acid derivatives
DE3805965A1 (de) 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
US5025001A (en) 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
EP0480061B1 (en) 1990-04-26 1996-12-04 Senju Pharmaceutical Co., Ltd. Hepatic disorder inhibitor
AU3071592A (en) 1991-11-14 1993-06-15 Brigham And Women's Hospital Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
NZ248332A (en) 1992-08-07 1995-01-27 Sankyo Co Hiv protease inhibitor and its use
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
JPH09508097A (ja) 1993-11-02 1997-08-19 アメリカ合衆国 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用
GB9423868D0 (en) 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
AU6782198A (en) 1997-03-27 1998-10-20 Trustees Of Boston University Novel antiplatelet agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412699A2 (en) * 1989-08-07 1991-02-13 Takeda Chemical Industries, Ltd. Nitrosothiol derivatives, their production and use
US5187305A (en) * 1990-11-26 1993-02-16 Glaxo Inc. S-nitroso-N-alkonoylpenicillamines
WO1995007691A1 (en) * 1993-09-17 1995-03-23 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces

Also Published As

Publication number Publication date
PT1157987E (pt) 2004-01-30
DE60005154T2 (de) 2004-07-08
AP2001002247A0 (en) 2001-09-30
EE04524B1 (et) 2005-08-15
KR20010101767A (ko) 2001-11-14
PL349006A1 (en) 2002-06-17
BR0007395A (pt) 2001-10-30
AP1439A (en) 2005-06-27
EA200100823A1 (ru) 2002-02-28
TR200102003T2 (tr) 2001-12-21
CA2359027C (en) 2008-10-28
ZA200106182B (en) 2002-10-28
HRP20010562B1 (en) 2010-08-31
JP2002535385A (ja) 2002-10-22
GB0120581D0 (en) 2001-10-17
US6800612B2 (en) 2004-10-05
HUP0105203A2 (en) 2002-06-29
CU23098A3 (es) 2005-11-18
NO326806B1 (no) 2009-02-16
IL144381A0 (en) 2002-05-23
CN1337946A (zh) 2002-02-27
BR0007395B1 (pt) 2010-11-16
GB2363604A (en) 2002-01-02
MXPA01007570A (es) 2003-05-14
EA003577B1 (ru) 2003-06-26
EP1157987B1 (en) 2003-09-10
IS2153B (is) 2006-10-13
DK1157987T3 (da) 2003-11-24
NO20013385D0 (no) 2001-07-06
ATE249428T1 (de) 2003-09-15
DE60005154D1 (de) 2003-10-16
CA2359027A1 (en) 2000-08-03
ES2206178T3 (es) 2004-05-16
AU764725B2 (en) 2003-08-28
HK1043586A1 (en) 2002-09-20
CZ298871B6 (cs) 2008-02-27
SI1157987T1 (en) 2004-02-29
WO2000044714A1 (es) 2000-08-03
CN1166631C (zh) 2004-09-15
YU53601A (sh) 2004-03-12
HUP0105203A3 (en) 2002-08-28
KR100671878B1 (ko) 2007-01-19
NO20013385L (no) 2001-09-17
GEP20043220B (en) 2004-04-26
BG64983B1 (bg) 2006-11-30
NZ513162A (en) 2003-01-31
EE200100389A (et) 2002-12-16
JP3795330B2 (ja) 2006-07-12
ES2147162B1 (es) 2001-03-16
PL202372B1 (pl) 2009-06-30
HRP20010562A2 (en) 2002-08-31
OA11823A (en) 2005-08-16
AU3046000A (en) 2000-08-18
IL144381A (en) 2005-08-31
GB2363604B (en) 2003-09-10
US20020058629A1 (en) 2002-05-16
CZ20012678A3 (cs) 2001-10-17
IS6020A (is) 2001-07-23
EP1157987A1 (en) 2001-11-28
ID29777A (id) 2001-10-11
RS50072B (sr) 2009-01-22
BG105824A (en) 2002-06-28
DE10083902T1 (de) 2002-01-10

Similar Documents

Publication Publication Date Title
ATE234099T1 (de) Immununterdrückende effekte von 8 substituierten xanthinderivaten
IL104090A (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing these compounds
EA200200299A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ
HUP9903047A2 (hu) Új benzotiazepinszármazékok csípőbéli epesav-transzportot és taurokolátfelvételt gátló aktivitással
DE69127690D1 (de) Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
EP2368900A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
BR0012443A (pt) Lipolìmero neutro e composições de lipossoma contendo o mesmo
NZ336629A (en) Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
KR910019612A (ko) 옥살릴아미노산 유도체, 이의 제조방법 및 프롤린 하이드록실라제 억제용 약제로서의 이의 용도
HUP9903336A2 (hu) Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények
RU2009103623A (ru) Производные теанина, их применение и способы их получения
EP1043322A4 (en) DERIVATIVES OF VITAMIN E
ES2147162A1 (es) "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ZA88995B (en) Peptide derivatives having a polycyclic nitrogenous structure,process for the preparation thereof and pharmaceutical compositions containing them
NO895123D0 (no) C63-amidderivater av 34-de(acetylglukosaminyl)-34-deoksyteicoplaniner og fremgangsmaate for deres fremstilling.
ZA935224B (en) Acyclic amidine group-containing diphosphonic acid derivatives for pharmaceutical compositions and preparation thereof
Poňka et al. The ability of exogenous heme to restore globin synthesis in reticulocytes with impaired heme formation
TH58472A3 (th) อนุพันธ์เฟนิลเอสเทอร์ของกรดแอลฟา-อะมิโน
NO865347L (no) Fremgangsmaate for fremstilling av pyrimido (5,4-b)(1,4)oxazinderivater.
TH42376A (th) ซัลโฟนามีด ที่มีพันธะที่-n ของเฮเทอโรไซคลิค ไธโอเอสเทอร์
ECSP993066A (es) Derivados de fenil esteres de alfa- aminoacidos y su uso como hipnoticos para la induccion y mantencion de la anestesia general

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000816

Kind code of ref document: A1

Effective date: 20000816

FD2A Announcement of lapse in spain

Effective date: 20180807